Skip to main content

Drug Interactions between Kalcinate and Syprine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

trientine calcium gluconate

Applies to: Syprine (trientine) and Kalcinate (calcium gluconate)

GENERALLY AVOID: Concurrent oral administration of mineral supplements or mineral-containing products may block the absorption of trientine, and vice versa. The mechanism is trientine chelation of polyvalent metal ions resulting in a nonabsorbable complex.

MANAGEMENT: In general, mineral supplements or mineral-containing products (e.g., antacids) should not be used in patients treated with trientine. If concomitant use is unavoidable, separation of administration times by at least two hours is advisable.

References

  1. "Product Information. Syprine (trientine)." Aton Pharma PROD (2001):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0

Switch to consumer interaction data

Drug and food interactions

Moderate

trientine food

Applies to: Syprine (trientine)

ADJUST DOSING INTERVAL: The gastrointestinal absorption of trientine may be decreased in the presence of food, resulting in reduced therapeutic effects.

MANAGEMENT: Trientine should be administered on an empty stomach, at least one hour before or two hours after meals and at least one hour apart from any other food, drug, or milk.

References

  1. "Product Information. Syprine (trientine)." Aton Pharma PROD (2001):

Switch to consumer interaction data

Moderate

calcium gluconate food

Applies to: Kalcinate (calcium gluconate)

ADJUST DOSING INTERVAL: Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.

MANAGEMENT: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. Agencia Española de Medicamentos y Productos Sanitarios Healthcare "Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
  5. Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub
  6. Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8
View all 6 references

Switch to consumer interaction data

Moderate

trientine food

Applies to: Syprine (trientine)

GENERALLY AVOID: Concurrent oral administration of mineral supplements or mineral-containing products may block the absorption of trientine, and vice versa. The mechanism is trientine chelation of polyvalent metal ions resulting in a nonabsorbable complex.

MANAGEMENT: In general, mineral supplements or mineral-containing products (e.g., antacids) should not be used in patients treated with trientine. If concomitant use is unavoidable, separation of administration times by at least two hours is advisable.

References

  1. "Product Information. Syprine (trientine)." Aton Pharma PROD (2001):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer